Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease.

Dallérac GM, Cummings DM, Hirst MC, Milnerwood AJ, Murphy KP.

Neuromolecular Med. 2016 Mar;18(1):146-53. doi: 10.1007/s12017-016-8384-z. Epub 2016 Jan 18.

PMID:
26782175
2.

Dysfunctional Dopaminergic Neurones in Mouse Models of Huntington's Disease: A Role for SK3 Channels.

Dallérac GM, Levasseur G, Vatsavayai SC, Milnerwood AJ, Cummings DM, Kraev I, Huetz C, Evans KA, Walters SW, Rezaie P, Cho Y, Hirst MC, Murphy KP.

Neurodegener Dis. 2015;15(2):93-108. doi: 10.1159/000375126. Epub 2015 Apr 9.

PMID:
25871323
3.

Brain endothelial miR-146a negatively modulates T-cell adhesion through repressing multiple targets to inhibit NF-κB activation.

Wu D, Cerutti C, Lopez-Ramirez MA, Pryce G, King-Robson J, Simpson JE, van der Pol SM, Hirst MC, de Vries HE, Sharrack B, Baker D, Male DK, Michael GJ, Romero IA.

J Cereb Blood Flow Metab. 2015 Mar;35(3):412-23. doi: 10.1038/jcbfm.2014.207. Epub 2014 Dec 17.

4.

MicroRNA-155 negatively affects blood-brain barrier function during neuroinflammation.

Lopez-Ramirez MA, Wu D, Pryce G, Simpson JE, Reijerkerk A, King-Robson J, Kay O, de Vries HE, Hirst MC, Sharrack B, Baker D, Male DK, Michael GJ, Romero IA.

FASEB J. 2014 Jun;28(6):2551-65. doi: 10.1096/fj.13-248880. Epub 2014 Mar 6.

PMID:
24604078
5.

Impaired long-term potentiation in the prefrontal cortex of Huntington's disease mouse models: rescue by D1 dopamine receptor activation.

Dallérac GM, Vatsavayai SC, Cummings DM, Milnerwood AJ, Peddie CJ, Evans KA, Walters SW, Rezaie P, Hirst MC, Murphy KP.

Neurodegener Dis. 2011;8(4):230-9. doi: 10.1159/000322540. Epub 2011 Feb 1.

PMID:
21282937
6.

Abnormal cortical synaptic plasticity in a mouse model of Huntington's disease.

Cummings DM, Milnerwood AJ, Dallérac GM, Vatsavayai SC, Hirst MC, Murphy KP.

Brain Res Bull. 2007 Apr 30;72(2-3):103-7. Epub 2006 Nov 16.

PMID:
17352933
7.

Progressive CAG expansion in the brain of a novel R6/1-89Q mouse model of Huntington's disease with delayed phenotypic onset.

Vatsavayai SC, Dallérac GM, Milnerwood AJ, Cummings DM, Rezaie P, Murphy KP, Hirst MC.

Brain Res Bull. 2007 Apr 30;72(2-3):98-102. Epub 2006 Nov 13.

PMID:
17352932
8.

Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease.

Cummings DM, Milnerwood AJ, Dallérac GM, Waights V, Brown JY, Vatsavayai SC, Hirst MC, Murphy KP.

Hum Mol Genet. 2006 Oct 1;15(19):2856-68. Epub 2006 Aug 11.

PMID:
16905556
9.

Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.

Milnerwood AJ, Cummings DM, Dallérac GM, Brown JY, Vatsavayai SC, Hirst MC, Rezaie P, Murphy KP.

Hum Mol Genet. 2006 May 15;15(10):1690-703. Epub 2006 Apr 6.

PMID:
16600988
10.
11.

Instability of a (CGG)98 repeat in the Fmr1 promoter.

Bontekoe CJ, Bakker CE, Nieuwenhuizen IM, van der Linde H, Lans H, de Lange D, Hirst MC, Oostra BA.

Hum Mol Genet. 2001 Aug 1;10(16):1693-9.

PMID:
11487573
14.
15.

Nucleosome assembly on methylated CGG triplet repeats in the fragile X mental retardation gene 1 promoter.

Godde JS, Kass SU, Hirst MC, Wolffe AP.

J Biol Chem. 1996 Oct 4;271(40):24325-8.

16.

Analysis of germline variation at the FMR1 CGG repeat shows variation in the normal-premutated borderline range.

Mornet E, Chateau C, Hirst MC, Thepot F, Taillandier A, Cibois O, Serre JL.

Hum Mol Genet. 1996 Jun;5(6):821-5.

PMID:
8776598
17.

FMR1 triplet arrays: paying the price for perfection.

Hirst MC.

J Med Genet. 1995 Oct;32(10):761-3. Review. No abstract available.

18.

The fragile X syndrome.

Flannery AV, Hirst MC, Knight SJ, Ritchie RJ, Davies KE.

Biochim Biophys Acta. 1995 Jun 9;1271(2-3):293-303. Review. No abstract available.

19.

Unusual (CGG)n expansion and recombination in a family with fragile X and DiGeorge syndrome.

Macpherson JN, Curtis G, Crolla JA, Dennis N, Migeon B, Grewal PK, Hirst MC, Davies KE, Jacobs PA.

J Med Genet. 1995 Mar;32(3):236-9.

20.

DNA testing for fragile X syndrome in schools for learning difficulties.

Slaney SF, Wilkie AO, Hirst MC, Charlton R, McKinley M, Pointon J, Christodoulou Z, Huson SM, Davies KE.

Arch Dis Child. 1995 Jan;72(1):33-7.

21.

The cloning of FRAXF: trinucleotide repeat expansion and methylation at a third fragile site in distal Xqter.

Ritchie RJ, Knight SJ, Hirst MC, Grewal PK, Bobrow M, Cross GS, Davies KE.

Hum Mol Genet. 1994 Dec;3(12):2115-21.

PMID:
7881407
22.

Evaluation of human microdissection clones from the FRAXA region as tools for comparative mapping in the mouse: isolation of a conserved genomic clone close to FMR1.

Blair HJ, Hirst MC, MacKinnon R, Davies KE, Boyd Y.

Mamm Genome. 1994 Sep;5(9):584-7. No abstract available.

PMID:
8000145
23.

Precursor arrays for triplet repeat expansion at the fragile X locus.

Hirst MC, Grewal PK, Davies KE.

Hum Mol Genet. 1994 Sep;3(9):1553-60.

PMID:
7833910
24.

Triplet repeat expansion at the FRAXE locus and X-linked mild mental handicap.

Knight SJ, Voelckel MA, Hirst MC, Flannery AV, Moncla A, Davies KE.

Am J Hum Genet. 1994 Jul;55(1):81-6.

25.

Origins of the fragile X syndrome mutation.

Hirst MC, Knight SJ, Christodoulou Z, Grewal PK, Fryns JP, Davies KE.

J Med Genet. 1993 Aug;30(8):647-50.

26.

Trinucleotide repeat amplification and hypermethylation of a CpG island in FRAXE mental retardation.

Knight SJ, Flannery AV, Hirst MC, Campbell L, Christodoulou Z, Phelps SR, Pointon J, Middleton-Price HR, Barnicoat A, Pembrey ME, et al.

Cell. 1993 Jul 16;74(1):127-34.

PMID:
8334699
27.

The identification of a third fragile site, FRAXF, in Xq27--q28 distal to both FRAXA and FRAXE.

Hirst MC, Barnicoat A, Flynn G, Wang Q, Daker M, Buckle VJ, Davies KE, Bobrow M.

Hum Mol Genet. 1993 Feb;2(2):197-200.

PMID:
8499907
28.

Identification of the FRAXE fragile site in two families ascertained for X linked mental retardation.

Flynn GA, Hirst MC, Knight SJ, Macpherson JN, Barber JC, Flannery AV, Davies KE, Buckle VJ.

J Med Genet. 1993 Feb;30(2):97-100.

29.

The fragile X syndrome.

Hirst MC, Knight SJ, Bell MV, Super M, Davies KE.

Clin Sci (Lond). 1992 Sep;83(3):255-64.

PMID:
1327643
30.

A microdeletion of less than 250 kb, including the proximal part of the FMR-I gene and the fragile-X site, in a male with the clinical phenotype of fragile-X syndrome.

Wöhrle D, Kotzot D, Hirst MC, Manca A, Korn B, Schmidt A, Barbi G, Rott HD, Poustka A, Davies KE, et al.

Am J Hum Genet. 1992 Aug;51(2):299-306.

31.

Analysis of mutations at the fragile X locus using the DNA probe Ox1.9.

Snow K, Doud L, Hagerman R, Hull C, Hirst MC, Davies KE, Thibodeau SL.

Am J Med Genet. 1992 Apr 15-May 1;43(1-2):244-54.

PMID:
1605198
32.

Molecular studies of the fragile X syndrome.

Knight SJ, Hirst MC, Roche A, Christodoulou Z, Huson SM, Winter R, Fitchett M, McKinley MJ, Lindenbaum RH, Nakahori Y, et al.

Am J Med Genet. 1992 Apr 15-May 1;43(1-2):217-23.

PMID:
1605194
33.

Mapping of FMR1, the gene implicated in fragile X-linked mental retardation, on the mouse X chromosome.

Laval SH, Blair HJ, Hirst MC, Davies KE, Boyd Y.

Genomics. 1992 Apr;12(4):818-21.

PMID:
1572655
34.

Genotype mosaicism in fragile X fetal tissues.

Wöhrle D, Hirst MC, Kennerknecht I, Davies KE, Steinbach P.

Hum Genet. 1992 Apr;89(1):114-6.

PMID:
1349561
35.

Molecular analysis of the fragile X syndrome.

Hirst MC, Knight SM, Nakahori Y, Roche A, Davies KE.

J Inherit Metab Dis. 1992;15(4):532-8. Review.

PMID:
1528014
36.

Molecular analysis of the fragile X syndrome.

Knight SJ, Hirst MC, Davies KE.

Dis Markers. 1992 Jan-Feb;10(1):1-5. Review.

PMID:
1424438
37.

Preparation of radiolabelled hybridization probes by STS labelling.

Hirst MC, Bassett JH, Roche A, Davies KE.

Trends Genet. 1992 Jan;8(1):6-7. No abstract available.

PMID:
1369736
38.

Genotype prediction in the fragile X syndrome.

Hirst MC, Nakahori Y, Knight SJ, Schwartz C, Thibodeau SN, Roche A, Flint TJ, Connor JM, Fryns JP, Davies KE.

J Med Genet. 1991 Dec;28(12):824-9.

39.

A YAC contig across the fragile X site defines the region of fragility.

Hirst MC, Rack K, Nakahori Y, Roche A, Bell MV, Flynn G, Christadoulou Z, MacKinnon RN, Francis M, Littler AJ, et al.

Nucleic Acids Res. 1991 Jun 25;19(12):3283-8.

40.

Linear order of new and established DNA markers around the fragile site at Xq27.3.

Hirst MC, Roche A, Flint TJ, MacKinnon RN, Bassett JH, Nakahori Y, Watson JE, Bell MV, Patterson MN, Boyd Y, et al.

Genomics. 1991 May;10(1):243-9.

PMID:
2045104
41.

Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome.

Bell MV, Hirst MC, Nakahori Y, MacKinnon RN, Roche A, Flint TJ, Jacobs PA, Tommerup N, Tranebjaerg L, Froster-Iskenius U, et al.

Cell. 1991 Feb 22;64(4):861-6.

PMID:
1997211
42.

Mapping of a cerebellar degeneration related protein and DXS304 around the fragile site.

Hirst MC, Bell MV, MacKinnon RN, Watson JE, Callen D, Sutherland G, Dahl N, Patterson MN, Schwartz C, Ledbetter D, et al.

Am J Med Genet. 1991 Feb-Mar;38(2-3):354-6.

PMID:
1673311
44.

Microdissection of the fragile X region.

MacKinnon RN, Hirst MC, Bell MV, Watson JE, Claussen U, Ludecke HJ, Senger G, Horsthemke B, Davies KE.

Am J Hum Genet. 1990 Aug;47(2):181-6.

45.

The use of filter-bound DNA fragments as templates for radiolabelling by random priming.

Hirst MC, Watson JE, Davies KE.

Nucleic Acids Res. 1989 Apr 11;17(7):2872. No abstract available.

46.

The c-Harvey-ras-1 oncogene in chromosome mediated gene transfer.

Morten JE, Hirst MC, Porteous DJ.

Anticancer Res. 1987 Jul-Aug;7(4A):573-88. Review.

PMID:
3310847

Supplemental Content

Loading ...
Support Center